Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Resch H  
Neues aus der Osteoporose-Therapie

Journal für Menopause 2004; 11 (3) (Ausgabe für Österreich): 25-29

Volltext (PDF)    Summary    Abbildungen   

Abb. 1: Chemische Struktur - Estradiol - SERMS Abb. 2: Chemische Struktur - Bisphosphonate Abb. 3: Chemische Struktur - Teriparatid

Keywords: MenopauseOsteoporosePräventionTherapie

Osteoporosis is a systemic skeletal disease. Its significance lies in the occurrence of fragility fractures. Typically, osteoporotic fractures occur at the vertebrae, the distal forearm, and the hip. The life-time risk of a fifty year old white woman to develop an osteoporotic fracture is almost 40 %. In countries of the Western world, the incidence of osteoporotic fractures exceeds the combined incidence of stroke, myocardial infarction and breast cancer. However, many pharmaceuticals, effective in the prevention of fractures, are available now. Currently, there is good evidence that alendronate, risedronate, and – in women who are vitamin D deficient – a combination of 1200 mg of calcium with 800 I.U. of vitamin D can substantially reduce the risk of hip fractures. The risk of vertebral fractures can be reduced by alendronate, risedronate, raloxifene, teriparatide, strontium ranelate and most likely also by calcitonin nasal-spray and etidronate. It is widely accepted that calcium and vitamin D, particularly in women who are deficient in calcium or vitamin D, constitute an important therapeutic adjunct.
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum